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Edited by Lukas HuberAbstract Tendon xanthomas (TX) are pathognomonic lipid
deposits commonly found in familial hypercholesterolemia
(FH) patients. The aim of this study was to determine whether
macrophages from FH patients with TX (TX+) have higher pre-
disposition to foam cells formation after oxidized LDL (oxLDL)
overload than those from FH patients without TX (TX), and if
their diﬀerential gene expression proﬁle could explain these dif-
ferent phenotypes. Total RNA pools from macrophages from FH
patients TX+ and TX were analyzed using Aﬀymetrix oligonu-
cleotide arrays to evaluate the gene expression proﬁle in presence
and absence of oxLDL. Also, the intracellular lipid content was
measured by ﬂuorescence ﬂow cytometry. Results of these stud-
ies suggest that macrophages from FH subjects TX+ compared
to those TX have a diﬀerential response to oxLDL, since they
show higher intracellular cholesterol ester accumulation and a
diﬀerential gene expression proﬁle. The gene array data were
validated by relative quantitative real-time RT-PCR and quanti-
tative ELISA in culture media and plasma samples. FH subjects
TX+ showed increased plasma tryptase, TNF-a, IL-8 and IL-6
concentrations. We propose that TX formation are associated
with higher intracellular lipid content, and higher inﬂammatory
response of macrophages in response to oxLDL.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Familial hypercholesterolemia (FH) is a genetic disorder of
lipoprotein metabolism characterized by very high plasma con-
centrations of LDL-cholesterol, deposition of cholesterol inAbbreviations: FH, familial hypercholesterolemia; TX, tendon xan-
thomas; oxLDL, oxidized LDL; TX+, with tendon xanthomas; TX,
without tendon xanthomas; ATD, Achilles tendon diameter; RFU,
relative ﬂuorescence units; oxLDL, without oxidized LDL; oxLDL+,
with oxidized LDL; MAS 5.0, Microarray Suite 5.0; P, present; A,
absent; M, marginal; I, increase; D, decrease; NC, no change
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neal arcus, and increased risk of premature coronary heart dis-
ease [1]. FH is a common autosomal codominant disease
caused by defects in the LDL receptor gene [2]. In heterozy-
gous FH patients, the clinical expression of FH is highly vari-
able in terms of the severity of hypercholesterolemia, the
presence of TX, and the age of onset and severity of coronary
heart disease, even in subjects sharing the same LDL receptor
gene defect [3].
TX are pathognomonic deposits of lipid and connective tis-
sue commonly found in patients with severe hyperlipidemia, as
occurs in FH. These deposits are highly speciﬁc of FH in sub-
jects with genetic high LDL-cholesterol, and current recom-
mendations include them as an important clinical diagnostic
criterion [4]. It has been reported that 29% of genetically diag-
nosed FH patients have Achilles TX diagnosed by sonography
[5]. Monocyte-derived foam cells due to intracellular accumu-
lation of oxidized LDL (oxLDL), extracellular unesteriﬁed and
esteriﬁed cholesterol and connective tissue are the main com-
ponents of tendon xanthomas [6,7]. Cholesterol dominates
among the lipid components, with unesteriﬁed cholesterol
accumulating predominantly in the extracellular space and
esteriﬁed cholesterol present both intra- and extracellularly
[6]. The composition of TX shows many similarities to athero-
sclerotic plaques, and, in fact, the presence of TX has been
associated with coronary disease in patients with heterozygous
FH in diﬀerent clinical studies [3,8,9].
In FH patients, elevation in serum LDL-cholesterol levels
secondary to the LDL receptor defect results in the formation
of oxidized or otherwise modiﬁed LDL, and in their uptake by
the macrophage scavenger receptors, leading to massive lipid
accumulation and foam cell formation [10]. Oxidatively modi-
ﬁed LDL epitopes are immunochemically detected intracellu-
larly in macrophages of TX from patients with FH [11].
Macrophages that internalize exogenous cholesterol repress
endogenous cholesterol biosynthesis and LDL receptor expres-
sion in response to cholesterol loading. Furthermore, these
cells have evolved other mechanisms to prevent the accumula-
tion of unesteriﬁed cholesterol, among them, cholesterol ester-
iﬁcation and cellular eﬄux of cholesterol and certain
cholesterol-derived oxysterols [12].
To date, the mechanism by which some FH subjects develop
TX and other FH subjects, do not, even having similar plasmablished by Elsevier B.V. All rights reserved.
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gene mutation, is unknown [3]. Previous reports have sug-
gested that the appearance of xanthomas in FH is controlled
by a second gene diﬀerent from the LDL receptor gene,
although not yet identiﬁed [13]. The aim of this study was to
determine whether macrophages from FH patients with TX
have higher predisposition to foam cells formation after
oxLDL overload than macrophages of FH patients without
TX, and if their diﬀerential gene expression proﬁle could
explain this lipid deposition in FH.
To evaluate our hypothesis, the intracellular cholesterol
ester content was compared by ﬂuorescence ﬂow cytometry,
and the gene expression proﬁle was analyzed using Aﬀymetrix
oligonucleotide arrays, in macrophages with and without oxi-
dized LDL stimulation from FH patients with both pheno-
types: with or without tendon xanthomas.2. Materials and methods
2.1. Study subjects
We selected 14 unrelated patients with genetic diagnosis of heterozy-
gous FH from Spain, 8 subjects (4 males and 4 females) with TX
detected before 50 years old, who constituted the TX+ group, and 6
subjects without TX (3 males and 3 females) older than 55 years, as
the TX group. Detection of TX was carried out by measurement
of the antero-posterior Achilles tendon diameter (ATD) with high res-
olution sonography. Based on the normal ATD deﬁned in a normolip-
idemic Spanish population, we considered positive presence of
xanthomas when ATD is higher than the mean + 10S.D. (males:
10.12 mm; females: 9.61 mm) [14]. The heterozygous FH patients
selected for this study carried the following LDL receptor mutations:
FH TX+ patients: 42C/G, C95R+D679E, 518delG (2390-1)G/C,
D200Y, 2085del19, P664L and (67+18)C/A+969delC; FH TX
patients: E10X (3 out of 6 patients), Q71E+(313+1)G/C, T433N and
42C/G.
All procedures were in accordance with the Helsinki Declaration of
1975, as revised in 1983, and all subjects gave written informed
consent.
2.2. Lipid quantiﬁcation
Fasting blood samples were drawn for measurements of plasma to-
tal cholesterol, HDL-cholesterol and triglycerides. Measurements
were performed with commercially available diagnostic kits (Boehrin-
ger–Mannheim, Indianapolis, IN, USA) in a central laboratory. Plas-
ma LDL-cholesterol was calculated according to the Friedewald
formula.
Lipoprotein (a) was determined by immunonephelometry with poly-
clonal antibodies (Beckman Coulter Inc., Miami, FL, USA). None of
the patients was under treatment with lipid lowering drugs at the time
of blood sampling. Distribution of quantitative variables was tested for
normality, and comparisons of lipid variables among the studied
groups were done by ANOVA one factor, considering statistical signif-
icance a value of P < 0.05.
2.3. Isolation and oxidation of LDL
LDL was isolated from one homozygous FH patient who was reg-
ularly treated with dextran sulfate LDL-apheresis [15]. The apolipo-
protein B-containing lipoproteins retained by dextran-sulfate were
eluted from the column with 0.702 M NaCl and subjected to a single
vertical spin density gradient ultracentrifugation in a VTI 50 rotor
(Beckman Coulter Inc.) [16]. The LDL fraction was collected from
the tube by gentle suction using a syringe with a long needle, and dia-
lyzed at 4 C for 24 h against EDTA-free PBS. The protein content
of LDL was determined by the method of Bradford using bovine ser-
um albumin (BSA) as standard. Native LDL was diluted to avoid
LDL aggregation to 200 lg of protein per milliliter with EDTA-free
PBS, and ﬁltered through a 0.45 lm ﬁlter (Millipore, Bedford, MA,
USA). Oxidation of LDL was performed by incubation at 37 C with
5 lmol/L CuCl2 for 24 h. The reaction was stopped by adding1 mmol/L EDTA and storing at 4 C. Oxidation of LDL was con-
ﬁrmed by Sudan Black LDL staining and agarose gel electrophoresis
[17], and conjugated diene formation assessment by spectrophotome-
try at 234 nm [18].
2.4. Isolation and culture of human monocyte-derived macrophages
Human mononuclear cells from the selected FH patients (8 TX+
and 6 TX subjects) were isolated by density gradient centrifugation
on Ficoll-Paque separating solution (Amersham Biosciences Corp.,
Piscataway, NJ, USA) from 40 mL of peripheral blood anticoagu-
lated with 10 U/mL lithium heparin. After gradient centrifugation,
plasma samples were stored at 80 C to be used for ELISA assays
and mononuclear cells were washed twice with RPMI-1640 (with 100
U/mL penicillin and 100 lg/mL streptomycin), resuspended in com-
plete RPMI-1640 (with GlutaMAX I, 25 mmol/L HEPES buﬀer, 100
U/mL penicillin, 100 lg/mL streptomycin, 1% non-essentials amino-
acids, and 2% sodium piruvate) containing 1% heat-inactivated
autologous serum, and plated at a density of 1.8 · 106 cells/mL dis-
tributed among four 25 cm2 culture ﬂasks (to be used for gene
expression analysis) and ﬁve 9.2 cm2 culture dishes (to be used for
intracellular lipid content analysis) for each subject. Cell viability
was >95% in all experiments, as assessed by trypan blue. After 2 h
at 37 C in 5% CO2, cells were washed twice with PBS (without cal-
cium nor magnesium, pH 7.4) to remove non-adherent cells, and
adherent monocytes were incubated for 24 h with complete RPMI-
1640 with 10% heat-inactivated autologous serum. After 24 h,
monocytes from 25 cm2 culture ﬂasks were washed with PBS and
incubated in macrophage-serum free medium (Invitrogen Corp.,
Carlsbad, CA, USA) (with 100 U/mL penicillin, 100 lg/mL strepto-
mycin and 2 mmol/L L-glutamine), and monocytes from 9.2 cm2
culture dishes were maintained with complete RPMI-1640 with
10% heat-inactivated autologous serum. On the 9th day, oxLDL
50 lg/mL was added to 2 out of 4 culture ﬂasks and 2 out of 5 cul-
ture dishes for each subject (oxLDL+ cultures), for 18 h incubation.
Remaining cultures were incubated with PBS instead of oxLDL
(oxLDL cultures).
All cellular experiments were performed at 37 C in a humidiﬁed
atmosphere of 5% CO2 in air, culture media were changed every 3
days, and macrophages were cultured for 10 days. Afterwards, macro-
phages were collected for intracellular lipid content analysis or total
RNA isolation.2.5. Intracellular lipid content quantiﬁcation
After 18 h incubation with oxLDL, macrophages were washed
twice with PBS and twice with 0.2% BSA-PBS. Then, cells were
incubated for 3–5 min at room temperature in 1 mmol/L EDTA-
PBS, and 15 min at 37 C in 0.25% tripsin, 1 mM EDTA. Cells were
collected by scrapping with a rubber policemen, pelleted and resus-
pended in 10 mmol/L EDTA-PBS. Nile Red (lipophylic ﬂuorescent
dye) stock solution (100 lg/mL in acetone) was diluted 100 times
with PBS and immediately used to stain cells. Resuspended cells
were incubated with Nile Red at 10 ng/mL during at least 10 min
at room temperature in the dark. After incubation, EDTA concen-
tration was increased to 30 mmol/L and stained cells were throughly
mixed, to minimize cell aggregation. All ﬂow cytometric studies
including data acquisition and analysis were performed using an
Epics XL cytometer (Beckman Coulter Inc.). At least 2500 cells were
analyzed for each sample. A protocol with ﬁxed forward and side
scatter, and positive stained cells thresholds was established. Three
samples were analyzed from each subject: non-stained macrophages
(incubated with the same volume percentage of acetone than stained
macrophages) (1 out of 5 culture dishes), stained macrophages from
cultures without oxLDL addition (2 out of 5), and stained macro-
phages from cultures with oxLDL addition (2 out of 5). The ﬂuores-
cence intensity emitted at k = 570–590 nm was collected and plotted
as histograms. Fluorescence of stained cells was normalized by sub-
tracting the background signal of non-stained macrophages. Values
of mean ﬂuorescence intensity, in relative ﬂuorescence units
(RFU), were used for comparison between macrophages from stud-
ied FH patients.
The signiﬁcance of diﬀerences between the ﬂuorescence intensity
means of the studied groups was analyzed with Students unpaired t-
test. Values were reported as the means ± S.E. Diﬀerences were consid-
ered statistically signiﬁcant if P < 0.05.
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On the 10th day of culture, total RNA was isolated from macro-
phages by guanidine isothiocyanate–phenol–chloroform extraction as
decribed by Chomczynski and Sacchi [19] using TRIzol-LS Reagent
(Invitrogen Corp.). Cells were washed twice with PBS, lysed directly
on culture ﬂasks adding 1 mL of TRIzol-LS Reagent per sample,
and gently collected by scrapping with a rubber policeman. Total
RNA was further puriﬁed by using RNeasy kit (Qiagen Inc., Valencia,
CA, USA) [20], being quantiﬁed by spectrophotometry at 260 nm and
assessed its purity by the ratio A260 nm/A280 nm. RNA integrity was ver-
iﬁed by visualization of ethidium bromide-stained 1% agarose gels.
Four total RNA pools from macrophage cultures from: (i) 6 FH pa-
tients TX and without oxLDL addition to the culture medium (pool
TX/oxLDL); (ii) 6 FH patients TX and with oxLDL addition
(pool TX/oxLDL+); (iii) 8 FH patients TX+ and without oxLDL
addition (pool TX+/oxLDL), and (iv) 8 FH patients TX+ and with
oxLDL addition (pool TX+/oxLDL+) were prepared, with the same
amount of total RNA from each macrophage culture from each pool,
to obtain a pool of 10 lg of total RNA.2.7. Target RNA preparation and array hybridization
Six lg total RNA was reverse transcribed by using oligo(dT)24
linked to a T7 RNA polymerase promoter sequence to prime cDNA
synthesis (SuperScript Choice System kit, Invitrogen Corp.). After sec-
ond-strand synthesis, biotinylated cRNA was produced by in vitro
transcription using biotinylated UTP and CTP (BioArray High-Yield
RNA Transcript Labelling kit, Enzo Diagnostics, Farmingdale, NY,
USA), and puriﬁed with RNeasy columns (Qiagen Inc.). Fifteen lg
biotinylated cRNA was fragmented in a MgOAc/KOAc buﬀer for
35 min at 94 C (to produce 35–200 bases fragments) and hybridized
to Aﬀymetrix Human Genome U133A GeneChip array (Aﬀymetrix
Inc., Santa Clara, CA, USA), at 45 C for 16 h in a hybridization oven
with constant rotation (60 rpm). Following hybridization, arrays were
washed and stained using the GeneChip Fluidics station (Aﬀymetrix
Inc.). Staining was performed using streptavidin–phycoerythrin conju-
gate (Molecular Probes Inc., Eugene, OR, USA), followed by the addi-
tion of biotinylated antibody to streptavidin (Vector Laboratories Inc.,
Burlingame, CA, USA), and ﬁnally with streptavidin–phycoerythrin
conjugate. The quality of the cRNA was tested evaluating the hybrid-
ization of fragmented cRNA to oligonucleotide probes matching the
5 0, middle and 3 0 sequences of b-actin and glyceraldehyde phosphate
dehydrogenase. cRNA samples with a 3 0/5 0 sequence ratio <3 were
considered to be of suﬃcient quality to further analyze the Aﬀymetrix
array.2.8. Microarray analysis: data quantiﬁcation, normalization and
comparison
GeneChip arrays were scanned using a GeneArray Scanner (Agilent
Technologies, Palo Alto, CA, USA). Following data acquisition,
scanned images were quantiﬁed using Microarray Suite 5.0 (MAS
5.0) software (Aﬀymetrix Inc.) yielding a signal intensity for each
probe on the GeneChip. The signal intensities from the probes for each
gene were then used to determine an overall expression level and mea-
sure of sequence-speciﬁc hybrization according to algorithms imple-
mented in MAS 5.0. The arrays were then linearly scaled to an
average expression level or total array signal intensity of 100 units
on each chip, to normalize data from diﬀerent arrays (signal_100).
MAS 5.0 software assigns every probe set a detection call (present
(P), absent (A), marginal (M)), which represents a qualitative indica-
tion of whether or not a transcript is detected within a sample. The
one-sided Wilconxons signed rank test is the statistical method
employed to generate the detection P-value. During the comparison
analysis, each probe set on the experimental array is compared to its
counterpart on the baseline array by the Wilconxons signed rank test,
and a change P-value is calculated indicating an increase (I), decrease
(D), or no change (NC) in gene expression. Signal and fold change are
computed using the one-step Tukeys Biweight method.
For comparison of global gene expression proﬁles between macro-
phages of FH TX+ patients and macrophages of FH TX patients,
a two-step strategy was used. First, comparisons were performed using
the MAS 5.0 software, deﬁning the pool FH TX as baseline. There-
fore, two comparisons, pool FH TX+/oxLDL vs pool FH TX/
oxLDL, and pool FH TX+/oxLDL+ vs pool FH TX/oxLDL+
were done. Second, genes diﬀerentially expressed (upregulated ordownregulated) were then ﬁltered by the following criteria: (i) detec-
tion call present in both compared arrays or at least in one of them,
(ii) probe set signal_100 greater than the mean signal on the array,
at least in one of the two compared arrays, and (iii) at least 2-fold
greater (upregulated genes) or 2-fold lower (downregulated genes) than
the signal on the deﬁned baseline array.
2.9. Molecular validation of microarray results by relative quantitative
real-time RT-PCR
One lg of each total RNA pool was treated with 1 U DNase I (Am-
bion Corp., Austin, TX, USA) in buﬀer 20 mM Tris–HCl, 50 mM
KCl, 2 mM MgCl2 at 37 C for 30 min, followed by DNase I inactiva-
tion at 65 C for 10 min, and was reverse transcribed with 200 U
SuperScript III RNase H Reverse Transcriptase (Invitrogen Corp.)
using 150 ng of random hexamer primers (Invitrogen Corp.) to prime
cDNA synthesis. The same protocol was followed with individual
RNA samples. Real-time RT-PCR was carried out using the ABI
Prism 7000 HT Sequence Detection System, TaqMan Universal PCR
Master Mix, unlabeled PCR primers and TaqMan MGB probes
(FAM dye-labeled) from Assay-on-Demand (cathepsin Z,
Hs_00179931_m1; RAB5C, Hs_00428044_m1; HLA-II-DQa1,
Hs_00824939_gH; IL-1b, Hs_00174097_m1; IER3, Hs_00174674_m1;
CXCL3, Hs_00171061_m1; PPARc, Hs_00234592_m1; IL-8,
Hs00174103_m1, and b-actin, Hs_99999903_m1) and Assay-on-Design
(tryptase a2, design based on sequence AF206665 (position
320–653 bp)) Gene Expression products, according to manufacturers
recommendations (Applied Biosystems, Foster City, CA, USA). All
samples were run in triplicate.
Sequence Detector Software (SDS) (Applied Biosystems) was used
for data analysis. A threshold cycle (CT) value was determined from
each ampliﬁcation plot. The relative expression ratios or fold changes
of target genes were calculated based on their real-time PCR eﬃcien-
cies (E) and the diﬀerence between mean CT of the sample from mac-
rophages from FH subjects TX+ and mean CT of the sample from
macrophages from FH subjects TX. E for each analyzed gene was
assessed by the slope of calibration curve, CT values on the y axis
and logarithm of the equivalent to the amount of total RNA on the
x axis (E = 10[1/slope]). Expression of target genes was normalized by
the endogenous reference gene b-actin [29]. CT data were analyzed
by Students unpaired t-test.
2.10. Quantitative ELISA of culture media and plasma samples
Quantiﬁcation of tryptase, IL-1b, TNF-a, IL-8 and IL-6 was carried
out in culture media after oxLDL incubation and in plasma samples
from the studied subjects by quantitative ELISA from Pharmacia
Diagnostics AB (Uppsala, Sweden) (UniCAP tryptase ﬂuoroenzyme-
immunoassay) and Beckman Coulter Inc. (IL-1b, ELISA IM3582;
TNF-a, ELISA IM1121; IL-8, ELISA IM2237; IL-6, ELISA
IM1120), according to manufacturers instructions. All measurements
were carried out in duplicate, and all samples were analyzed in the
same microtitre plate to minimize run-to-run variability. ELISA data
were analyzed by Students unpaired t-test.3. Results and discussion
3.1. Description of subjects
Anthropometric and lipid data of the subjects included in
this study are shown in Table 1. FH patients TX+ showed
an antero-posterior ATD of 20.43 ± 1.57 mm (means ± S.E.),
and FH patients TX an ATD of 7.53 ± 0.52 mm
(P < 0.0001). No statistical diﬀerences between FH patients
TX+ and TX in relation to gender, total cholesterol, HDL-
cholesterol, LDL-cholesterol, triglycerides and lipoprotein (a)
were observed.
3.2. Intracellular cholesterol ester content
To analyze cholesterol ester accumulation, macrophages
were incubated without or with oxLDL, stained with Nile
Red, and analyzed by ﬂuorescence ﬂow cytometry. The use
Fig. 1. Comparison of eﬀects of oxLDL on intracellular cholesterol
ester content by ﬂuorescence ﬂow cytometry analysis in macrophages
from FH subjects TX and TX+ stained with Nile Red. (a) Cells
analyzed for each sample. Representation of log ﬂuorescence intensity
vs side scatter. (b) Representation of cell number vs log ﬂuorescence
intensity. D line, total population of analyzed macrophages; I line,
subpopulation of macrophages with lower mean ﬂuorescence intensity;
H line, subpopulation of macrophages with higher mean ﬂuorescence
intensity. (c) Comparison of mean ﬂuorescence intensity of D region
between macrophages from studied FH subjects, TX vs TX+.
Fluorescence intensity is presented as box whisker plots, the box
represents the interquartile range, and the whiskers are lines that
extend from the box to the highest and lowest values. A line across the
box indicates the median. (d) Comparison of macrophage subpopu-
lation with higher ﬂuorescence intensity (region H) between macro-
phages from studied FH subjects, TX vs TX+. Percentage of cells in
H region is presented as box whisker plots.
Table 1
Anthropomethric and lipid data of the FH subjects included in this
study according to absence or presence of tendon xanthomas
FH TX FH TX+ P
n 6 8
Age (years) 61.17 ± 4.92 54.00 ± 2.96
Gender
Male/female 3/3 4/4 NS
ATD (mm) 7.53 ± 0.52 20.43 ± 1.57 0.0001
BMI (kg/m2) 27.50 ± 0.83 23.96 ± 1.74 NS
Total cholesterol (mmol/L) 10.45 ± 0.57 11.65 ± 0.55 NS
LDL-cholesterol (mmol/L) 8.77 ± 0.54 9.70 ± 0.44 NS
HDL-cholesterol (mmol/L) 1.18 ± 0.12 1.47 ± 0.13 NS
Triglycerides (mmol/L) 1.07 ± 0.14 1.07 ± 0.09 NS
Lipoprotein (a) (lmol/L) 1.05 ± 0.56 1.37 ± 0.12 NS
Quantitative values are presented as means ± S.E. Statistical analysis
was performed by ANOVA one factor. Signiﬁcance level was deﬁned
as P < 0.05. FH, familial hypercholesterolemia; TX, without tendon
xanthomas; TX+, with tendon xanthomas; ATD, antero-posterior
Achilles tendon diameter; BMI, body mass index; NS, non-signiﬁcant.
4506 M. Artieda et al. / FEBS Letters 579 (2005) 4503–4512of Nile Red for labeling intracellular lipid droplets was ﬁrst
reported by Greenspan et al. [21] Nile Red is an excellent vital
stain for detection of intracellular neutral lipids (cholesterol
esters, triglycerides and phospholipids) by ﬂuorescence micros-
copy and ﬂow cytoﬂuorometry. Foam cell formation is charac-
terized by an increase of cholesterol esters, while cellular
triglyceride and phospholipid levels remain essentially
unchanged [22]. Moreover, a good agreement between the ﬂuo-
rescence signal with lipid loading and quantiﬁcation of the cel-
lular cholesterol esters by gas–liquid chromatography has been
demonstrated [23]. Therefore, the cell assay used in this study
can be considered representative of the intracellular cholesterol
ester content.
Comparing mean ﬂuorescence intensity data from macro-
phages without oxLDL addition to the culture media, no sta-
tistical diﬀerences between macrophages from FH patients
TX+ compared with FH subjects TX were observed
(P = 0.201). Interestingly, when oxLDL was added to culture
media, macrophages from FH patients TX+ had higher aver-
age ﬂuorescence intensity values than FH subjects TX,
34 ± 4.8 vs 21 ± 1.5 RFU (means ± S.E.), respectively
(P = 0.038), as it is shown in Fig. 1(c). Indeed, no overlapping
values between both compared groups were observed. Histo-
gram in Fig. 1(b) shows two subpopulations of macrophages,
one with lower mean ﬂuorescence intensity (I), and the other
one with higher ﬂuorescence intensity values (H). FH subjects
TX+ showed higher percentages of macrophage subpopulation
with higher ﬂuorescence intensity (%H) than FH subjects
TX, 62 ± 4.7% vs 41 ± 5.9 (means ± S.E.), respectively
(P = 0.022) (Fig. 1(d)). Therefore, these results would suggest
that macrophages from FH subjects TX+ have a higher predis-
position to form foam cells in response to oxLDL than macro-
phages from FH patients TX. The presence of macrophages
with lower ﬂuorescence intensity is due to the large variation in
human foam cell formation among individuals, and also to the
fact that transformation from macrophages to foam cells is a
continuous process with diﬀerences among macrophage sub-
populations [22].
3.3. Macrophage gene expression proﬁle
To determine the genome-wide changes in gene expression
that accompany TX in FH patients, expression analysis usingthe Aﬀymetrix U133A GeneChip was performed. This array
contains 22283 probe sets designed to detect the expression
of approximately 20000 diﬀerent transcripts derived from
approximately 15000 well-substantiated genes. The expression
of these 20000 transcripts represented on the array was quan-
tiﬁed in pooled total RNA samples isolated from macrophages
of 8 FH patients TX+, and from macrophages of 6 FH pa-
tients TX. We have submitted obtained microarray data to
the microarray database MIAME (Accession No. E-MEXP-
360).
3.3.1. Macrophage gene expression proﬁle changes without
oxLDL stimulation. Overall, 10013 probe sets (44.9%) were
expressed in macrophages from FH patients TX+ (identiﬁed
as present by MAS 5.0 software), and 10019 probe sets
(45.0%) in macrophages from FH patients TX. Using the
Wilcoxons signed rank test of the MAS 5.0 software as criteria
for statistical signiﬁcance, 401 probe sets were identiﬁed as
increased and 347 probe sets as decreased in macrophages
from FH patients TX+, deﬁning the pool FH TX/oxLDL
as baseline. To identify genes that are likely to be diﬀerentially
expressed in macrophages from FH patients TX+, we ﬁltered
genes according to criteria described in Section 2. Twelve
probe sets met these criteria (Table 2): 7 upregulated and 5
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ulated oxLDL macrophages revealed that among the genes dif-
ferentially expressed in macrophages from FH subjects TX+
cathepsin Z, LIMK1, RAB5C, HLA-II-DQa1 and FccRIIb
were upregulated, and CYP27B1 was downregulated.
Cathepsin Z is a lysosomal cysteine proteinase. Increased
expression of several cathepsins in atherosclerotic lesions sug-
gests that these proteases may participate in the remodelling of
extracellular matrix associated with the atherosclerotic process
[24].
LIMK1 is involved in reorganization of actin cytoskeleton,
and it has been attributed a possible role in regulating cell cycle
progression, G2 to M phase [25]. Therefore, a higher LIMK1
gene expression of macrophages from FH subjects XT+ would
suggest that they could have increased proliferative potential
and cell survival than macrophages from FH XT.
RAB5C is a geranylgeranylated protein member of the ras
family. RAB5 proteins may play a regulatory role in medi-
ating lipoprotein endocytosis through scavenger receptors
and recycling [26]. The higher expression of RAB5C in mac-
rophages from FH subjects TX+ could indicate that their
macrophages could have higher lipoprotein endocytosis
through scavenger receptors than macrophages from FH
subjects TX. According with this, in our study we have
found that macrophages from FH subjects TX+ have higher
intracellular cholesterol ester content than macrophages
from FH subjects TX, possibly due to a higher lipoprotein
endocytosis.
HLA-II-DQa1 is a member of the family of cell surface pro-
teins HLA-II, which are involved in the activation of T lym-
phocytes and in the control of the immune response.
Immune cells with an increased expression of HLA-II (DR
and DQ) molecules are able to produce signiﬁcant amounts
of inﬂammatory cytokines, such as IL-1b, IL-6, IL-12 and
TNF-a, as well as chemokines such as IL-8. Therefore, the
higher HLA-II-DQ expression in macrophages from FH sub-
jects TX+ could suggest a more reactive immunophenotype.
Interestingly, HLA-II protein expression has been recently
observed in atherosclerotic plaques, on endothelial cells, mac-
rophages, and smooth muscle cells [27].
FccRs are specialized cell surface receptors that coordinately
regulate immune responses. FccRs are critical for the develop-
ment of inﬂammation, possibly by maintaining or enhancing
inﬂammatory cytokine and chemokine production [28]. The
higher gene expression of FccRIIb in macrophages from FH
subjects TX+ could be associated with a higher susceptibility
to an increased expression of proinﬂammatory molecules. Be-
sides, murine FccRIIb has been reported to bind oxLDL [29],
as scavenger receptors class A and B. However, in humans,
FccRIIb can mediate uptake of lipoprotein immune com-
plexes, but does not mediate uptake of oxLDL [30].
CYP27B1 is a cytochrome P450, member of family 27,
which hydroxylates 25-hydroxyvitamin D3 at the 1-a position,
synthesizing the active form of vitamin D3. Thus, this enzyme
regulates the level of biologically active vitamin D and plays an
important role in calcium homeostasis. A downregulation of
the oxysterol 7a-hydroxylase CYP27B1 was observed in mac-
rophages from FH subjects TX+. The cause of the rare meta-
bolic disease cerebrotendinous xanthomatosis (CTX) is a
defect in other member of the CYP27 family, CYP27A1.
Patients with CTX are typically normolipidemic, but have
prominent xanthomas in tendons and brain. CYP27A1 is an
4508 M. Artieda et al. / FEBS Letters 579 (2005) 4503–4512oxysterol 7 a-hydroxylase that metabolizes cytotoxic oxyster-
ols to dihydroxy metabolites, which are more soluble and read-
ily excreted from extrahepatic tissues. CYP27A1 is an
important enzyme for cholesterol homeostasis in human mac-
rophages, especially for the eﬄux of both cholesterol and cho-
lestanol from tendons [31].
3.3.2. Macrophage gene expression proﬁle changes stimu-
lated by oxLDL. Overall, 9036 probe sets (40.6%) were
expressed in macrophages from FH patients TX+ (identiﬁed
as present by MAS 5.0 software), and 9886 probe sets
(44.4%) in macrophages from FH patients TX. Using the
MAS 5.0 software criteria for statistical signiﬁcance, 310 probe
sets were identiﬁed as increased and 799 probe sets as
decreased, in macrophages from FH patients TX+, deﬁning
the pool FH TX/oxLDL+ as baseline. We ﬁltered genes
according to criteria described in Section 2 to identify genes
that are likely to be diﬀerentially expressed in macrophages
from FH patients TX+ after oxLDL incubation. Thirty seven
probe sets met these criteria (Table 3): 33 upregulated and 4
downregulated, and corresponded to 29 genes and 1 EST: 26
genes upregulated, and 1 EST and 3 genes downregulated.
Included among the changed expression genes are the fol-
lowing chemokines: MIP2b (CXCL3), GROb (CXCL2) and
MIP1 b (CCL4); proinﬂammatory cytokines: IL-1b, IL-8
and IL-6 (with a fold change of 1.9); molecules involved in cell
adhesion: ICAM1, TNFaIP6 and DOCK4; cell cycle or sur-
vival factors: IER3, G0S2, TRAF1, SFRS6 and GBP1; meta-
bolic pathways enzymes: AKR1C1, AKR1C2, ADA and
SOD2; ﬁbrinolytic mediators: UPAR; proteasas: tryptases
(TPBa1, TPBa2 and TPBb1); proteasas inhibitors: TIMP1;
transcription regulatory factors: IjBa; transcription factors:
PPARc, and genes involved in immune response: TLR1 and
HLA-II-DQa1.
Comparison of gene expression proﬁle of oxLDL stimu-
lated macrophages revealed signiﬁcant expression changes in
macrophages from FH subjects TX+ in genes related to
inﬂammation compared to macrophages from those TX,
as upregulation of several chemokines, proinﬂammatory cyto-
kines and adhesion molecules was observed. The enhanced
chemokine expression of macrophage inﬂammatory protein-
2b (MIP2b) or CXCL3, IL-8 or CXCL8, GROb or CXCL2
and MIP1b or CCL4, and of the adhesion molecule ICAM1
as diﬀerential oxLDL response of macrophages from FH sub-
jects TX+ could promote a high recruitment and activation
of macrophages and lymphocytes within tendon xanthomato-
sis lesion. Recently, an enhanced chemokine release from
peripheral blood mononuclear cells has been related to the
presence of xanthomas/xanthelasms [32], and ICAM1 has
been identiﬁed as one of the adhesion molecules induced by
oxLDL in xanthoma lesions that contributes to foam cell
recruitment inducing adhesion of monocytes to human der-
mal microvascular endothelial cells [33]. Moreover, IL-1b is
only expressed in macrophages from FH subjects TX+, and
showed a spectacular upregulation, approximately 17-fold.
IL-1b is an important mediator of inﬂammatory responses
and has been found in atherosclerotic plaques [34]. IL-1b
activates NF-jB, an important transcription factor for multi-
ple genes involved in immunological, proliferative and inﬂam-
matory responses. NF-jB may play an important role in
atherosclerosis by modulating gene expression in cells partic-
ipating in lesion formation [35]. Several genes upregulated in
macrophages from FH subjects TX+ are NF-jB-dependent,as the described chemokines, proinﬂammatory cytokines
and adhesion molecules [36]. Therefore, these ﬁndings appear
to suggest NF-jB pathway activation. However, a NF-jB
inhibitory protein, IjBa, is upregulated in macrophages from
FH subjects TX+. The upregulation of IjBa involves both
NF-jB activation, since the IjBa transcription is NF-jB-
dependent, and reduction of translocation of NF-jB to the
nucleus. Since IL-1b activates the NF-jB pathway, it could
oﬀset this inhibitory eﬀect, keeping the NF-jB activation in
macrophages from FH subjects TX+.
PPARs have been shown to downregulate inﬂammatory
response genes by negatively interfering with the STAT, AP-
1 and NF-jB transcriptional pathways [37]. Anti-inﬂamma-
tory actions of PPARs were ﬁrst reported in monocytes and
macrophages for PPARc [38,39]. Subsequent ﬁndings indi-
cated that both PPARa and PPARd have also anti-inﬂamma-
tory properties controlling the inﬂammatory status of the
macrophage [40]. PPARc inhibits the transcriptional activity
of NF-jB by physical interaction with p65 [41]. The ﬁnding
that PPARc is downregulated in macrophages from FH
patients TX+ in this study would suggest a lower downregula-
tion of inﬂammatory response genes of the NF-jB pathway
than in macrophages from FH patients TX.
Therefore, the higher inﬂammatory response to oxLDL of
macrophages from FH subjects TX+ compared with those
TX could contribute to the development of xanthomatous
lesions, as well as could explain the association between pres-
ence of TX with premature coronary heart disease. Besides,
gene expression proﬁle comparison revealed, in both with
and without oxLDL cultures, that a HLA-II-D gene relevant
to macrophage activation was upregulated, HLA-II-DQa1.
Therefore, our results clearly show that macrophages from
FH subjects TX+ compared to those TX diﬀer not only in
their immunophenotype, due to a higher HLA-II-D molecules
expression, but also in their functionality, because of higher
cytokine and chemokine production.
Tryptases are trypsin-like serine proteases which are se-
creted as catalytic active and heparin-bound oligomers that
resist inactivation by plasma antiproteases [42]. Tryptases
have been described as the most speciﬁc marker in vivo of
mast cell activation in humans, since they are the most abun-
dant secretory mediator of these cells [43]. Expression of tryp-
tase mRNA was also detected in two human monocytic cell
lines and in normal human peripheral blood monocytes. Re-
cently, a serine protease predominantly expressed in macro-
phages that shares 44% identity with tryptase-b has been
identiﬁed, and mapping also to human chromosome
16p13.3 as tryptases [44]. Interestingly, a study revealed that
mast cell tryptase can degrade HDL3 and thereby may alter
the functional properties of HDL3 as an eﬃcient acceptor
of cellular cholesterol [45]. Therefore, stimulated mast cells
found in human arterial intima may play a role in retarding
the eﬄux of cellular cholesterol from macrophage foam cells
in vivo [46]. Both a strong upregulation of tryptase expres-
sion in macrophages from FH subjects TX+ and a speciﬁc
tryptase expression, as macrophages from FH subjects TX
did not show tryptase expression, have been observed. Since
the released tryptase is resistant to physiological protease
inhibitors, and tryptase is stabilized by proteoglycans, which
are present in TX, it appears conceivable that, in vivo, tryp-
tase-secreting macrophage cells could reduce the eﬄux of
cholesterol from macrophages, and thus contribute to the
Table 3
Genes diﬀerentially expressed by macrophages from FH subjects TX+ compared to TX in response to oxLDL stimulation
Gene name Gene symbol Map location Accession Number FH TX FH TX+ FH TX+ vs
FH TX
P
Aﬀymetrix GenBank Signal_100 Signal_100 Fold change
Tryptase alpha 2 TPSa2 16p13.3 210084_x_at AF206665.1 3.9 A 100.1 P 21.1 I 0.00003
Tryptase alpha TPSa 16p13.3 207741_x_at NM_003293.2 40.4 A 137.3 P 3.0 I 0.00002
Tryptase beta 1 TPSb1 16p13.3 205683_x_at NM_003294.2 18.2 A 111.8 P 8.6 I 0.00002
Tryptase alpha 2 TPSa2 16p13.3 215382_x_at AF206666.1 12.9 A 113.4 P 6.5 I 0.00010
Interleukin 1, beta IL1b 2q14 205067_at NM_000576.1 62.0 A 1122.8 P 17.1 I 0.00002
Interleukin 1, beta IL1b 2q14 39402_at M15330 33.7 A 555.9 P 16.0 I 0.00000
TNF, alpha-induced protein 6 TNFaIP6 2q23.3 206025_s_at AW188198 59.1 P 384.6 P 4.9 I 0.00002
TNF, alpha-induced protein 6 TNFaIP6 2q23.3 206026_s_at NM_007115.1 74.1 P 194.6 P 4.3 I 0.00002
Immediate early response 3 IER3 6p21.3 201631_s_at NM_003897.1 45.6 P 150.7 P 4.3 I 0.00002
CXC chemokine ligand 3 CXCL3 4q21 207850_at NM_002090.1 24.1 P 113.6 P 4.0 I 0.00002
CXC chemokine ligand 2 CXCL2 4q21 209774_x_at M57731.1 129.7 P 374.4 P 3.5 I 0.00002
CC chemokine ligand 4 CCL4 17q12 204103_at NM_002984.1 62.7 A 116.6 P 2.3 I 0.00008
Interleukin 8 IL8 4q13-q21 211506_s_at AF043337.1 504.6 P 1666.5 P 3.7 I 0.00002
Interleukin 8 IL8 4q13-q21 202859_x_at NM_000584.1 2834.1 P 3661.9 P 2.0 I 0.00005
Putative G0/G1 switch gene G0S2 1q32.2-q41 213524_s_at NM_015714.1 71.0 P 169.6 P 3.2 I 0.00002
NFkB inhibitor, alpha IjBa 14q13 201502_s_at AI078167 246.2 P 658.5 P 2.8 I 0.00002
Aldo-keto reductase family 1, C1 AKR1C1 10p15-p14 216594_x_at S68290.1 609.0 P 1362.4 P 2.6 I 0.00004
Aldo-keto reductase family 1, C1 AKR1C1 10p15-p14 204151_x_at NM_001353.2 870.5 P 2058.1 P 2.5 I 0.00002
Aldo-keto reductase family 1, C2 AKR1C2 10p15-p14 211653_x_at M33376.1 566.4 P 1457.7 P 2.5 I 0.00008
Aldo-keto reductase family 1, C2 AKR1C2 10p15-p14 209699_x_at U05598.1 407.2 A 745.1 P 2.1 I 0.00035
Adenosine deaminase ADA 20q12-q13.11 204639_at NM_000022.1 55.6 P 121.1 P 2.5 I 0.00086
ICAM 1 (CD54) ICAM1 19p13.3-p13.2 202637_s_at AI608725 128.1 A 291.8 P 2.5 I 0.00005
ICAM 1 (CD54) ICAM1 19p13.3-p13.2 202638_s_at NM_000201.1 65.9 P 228.2 P 2.3 I 0.00016
MHC, class II, DQ alpha 1 HLA-II-DQa1 6p21.3 213831_at X00452.1 95.0 P 187.3 P 2.3 I 0.00002
PHD ﬁnger protein 10 PHF10 6q27 221786_at AF055030.1 271.7 P 617.1 P 2.3 I 0.00002
Tissue inhibitor of metalloproteinase 1 TIMP1 Xp11.3-p11.23 201666_at NM_003254.1 188.6 P 425.9 P 2.1 I 0.00002
Guanylate binding protein 1 GBP1 1p22.2 202269_x_at BC002666.1 93.5 P 193.2 P 2.1 I 0.00002
Superoxide dismutase 2, mitochondrial SOD2 6q25.3 215223_s_at W46388 566.7 P 1210.2 P 2.1 I 0.00225
PHD ﬁnger protein 10 PHF10 6q27 221787_at AF055030.1 138.4 P 311.9 P 2.1 I 0.00002
DOCK4 DOCK4 7q31.1 205003_at NM_014705.1 49.5 P 105.1 P 2.0 I 0.00004
TNF receptor-associated factor 1 TRAF1 9q33-q34 205599_at NM_005658.1 56.2 P 104.5 P 2.0 I 0.00304
Splicing factor, arginine/serine-rich 6 SFRS6 20q12-q13.1 206108_s_at NM_006275.1 46.6 P 110.6 P 2.0 I 0.00077
Urokinase plasminogen activator receptor UPAR 19q13 211924_s_at AY029180.1 390.2 P 684.1 P 2.0 I 0.00003
EST 212509_s_at BF968134 208.1 P 83.9 P 2.6 D 0.99997
PPAR gamma PPARc 3p25 208510_s_at NM_015869.1 137.5 P 59.9 P 2.0 D 0.99969
Toll-like receptor 1 TLR1 4p14 210176_at AL050262.1 199.2 P 82.4 P 2.0 D 0.99998
LR8 protein LR8 7q36.1 220532_s_at NM_014020.1 390.5 P 209.9 P 2.0 D 0.99997
FH, familial hypercholesterolemia; TX, without tendon xanthomas; TX+, with tendon xanthomas; Signal_100, signal intensities from the probes for each gene scaled to a total array signal intensity
of 100 units; P, present; A, absent; I, increase; D, decrease. Fold change was computed using the one-step Tukeys Biweight method. P values close to 0 indicate increase in transcript expression level,
and close to 1 indicate decrease in transcript expression level.
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4510 M. Artieda et al. / FEBS Letters 579 (2005) 4503–4512formation and maintenance of foam cells in tendon xanthom-
atous lesions. Besides, tryptase has been reported to be an
important mediator of inﬂammation activating peripheral
mononuclear cells for the release of TNF-a, IL-6 and IL-1b
[47]. Moreover, it has been suggested that tryptase contribute
to matrix degradation within atherosclerotic plaques indi-
rectly by activation of MMPs or directly by digestion of pla-
que matrix proteins [48].Table 4
ELISA data of the FH subjects included in this study according to
absence or presence of tendon xanthomas
FH TX FH TX+ P
n 6 8
Tryptase (lg/L)
oxLDL+ UD 2.70a
Plasma 2.59 ± 0.30 6.02 ± 1.02 0.015
IL-1b (ng//L)
oxLDL+ 87.98 ± 25.65 80.50 ± 17.51 NS
Plasma 14.37 ± 12.23 15.57 ± 7.96 NS
TNF-a (ng//L)
oxLDL+ 25.24 ± 9.95 54.78 ± 17.17 NS
Plasma 78.75 ± 19.02 131.32 ± 38.48 NS
IL-8 (ng//L)
oxLDL+ 56.23 ± 20.91 147.42 ± 18.26 0.007
Plasma 229.77 ± 35.26 369.23 ± 98.58 NS
IL-6 (ng//L)
oxLDL+ 14.57b 433.68 ± 213.87b
Plasma 24.48 ± 10.31 74.94 ± 20.25 0.050
ELISA data are expressed as mean ± SE and were analyzed by Stu-
dents unpaired t-test. FH, familial hypercholesterolemia; TX, with-
out tendon xanthomas; TX+, with tendon xanthomas; oxLDL+,
macrophage culture media after oxLDL stimulation; UD, undetect-
able; NS, non-signiﬁcant.
aTryptase was only detected in 1 out of 14 culture media (FH subject
TX+).
bIL-6 was only detected in 4 out of 14 culture media (1 FH subject
TX and 3 FH subjects TX+).3.4. Molecular validation of macrophage gene expression proﬁle
changes
Microarray analysis suggested that macrophages from FH
subjects TX+ compared to those TX showed a diﬀerential
response to oxLDL, whereas in absence of oxLDL stimulation
only 12 genes were diﬀerentially expressed, although with fold
changes lower than 3-fold. To corroborate these ﬁndings, rel-
ative quantitative real-time RT-PCR experiments were per-
formed using the same total RNA pools as that used in the
microarray analyses, and quantitative ELISA determinations
were carried out in individual samples (to avoid the problem
with potential individual variability of the samples when pools
are used): macrophage culture media after oxLDL incubation
and plasma from studied subjects. Besides, real-time RT-PCR
experiments for molecular validation of IL-8 were done with
individual RNA samples (5 out of 6 FH TX and 7 out of 8
FH TX+) to verify that microarray results are not biased by
one or two outliers.
We tested three genes by real-time RT-PCR, cathepsin Z,
RAB5C and HLA-II-DQa1, to verify the results obtained
from the comparison pool TX+/oxLDL vs pool TX/
oxLDL. The analysis conﬁrmed the upregulation of HLA-
II-DQa1, 2.5-fold increase, whereas cathepsin Z and RAB5C
mRNA levels, 1.4-fold and 1.3-fold increases, respectively, re-
sulted in substantial declines compared to that obtained by
microarray analysis (Table 2).
To verify the macrophage gene expression proﬁle changes
identiﬁed by microarray analysis after stimulation with
oxLDL, a second series of relative quantitative real-time RT-
PCR experiments were performed. We tested six genes from
the results obtained from the comparison pool TX+/oxLDL+
vs pool TX/oxLDL+, selected in function of their involve-
ment in remodelling, inﬂammation or cell cycle: tryptase a2,
IL-1b, IER3, CXCL3, HLA-II-DQa1 and PPARc. The fold
changes obtained were the following: 31.2-fold, 45.4-fold,
4.5-fold, 4.2-fold, 1.7-fold increases and 2.3-fold decrease,
respectively. These results were in good agreement with those
from microarray data (Table 3). It is notable that the fold
increases in tryptase a2 and IL-1b mRNA levels obtained by
real-time RT-PCR were considerably higher than that
obtained by microarray analysis.
Real-time RT-PCR experiments with individual RNA sam-
ples (5 out of 6 FH TX and 7 out of 8 FH TX+) showed that
the mean CTs were the following: 24.2, 24.6, 25.3, 25.6 and
21.5 for the samples TX/oxLDL+ and 19.7, 23.9, 21.7,
17.5, 20.5, 16.1 and 17.4 for the samples TX+/oxLDL+. There
were signiﬁcant diﬀerences in normalized CT distribution be-
tween both groups (P = 0.006), and the fold change obtained
was 2.8-fold increase, result in agreement with that from the
microarray data (Table 3).
We examined the release of tryptase, IL-1b, TNF-a, IL-8
and IL-6 to culture media from oxLDL stimulated macro-phages and plasma concentrations in the studied subjects. ELI-
SA data are shown in Table 4. Macrophages from FH subjects
TX+ compared to those from FH subjects TX released
markedly enhanced levels of IL-8 (147.42 ± 18.26 vs
56.23 ± 20.91 ng/L (means ± S.E.), respectively, P = 0.007),
and TNF-a (54.78 ± 17.17 vs 25.24 ± 9.95 ng/L, respectively,
P = 0.200). Interestingly, tryptase and IL-6 were only detected
in one sample from a FH subject TX+, and in four samples
from FH subjects (1 TX and 3 TX+), respectively. There
were no signiﬁcant diﬀerences in culture media and plasma
concentrations of IL-1b between the compared FH subjects.
FH subjects TX+ compared to those TX showed increased
plasma concentrations of tryptase (6.02 ± 1.02 vs 2.59 ±
0.30 lg/L, respectively, P = 0.015), TNF-a (131.32 ± 38.48 vs
78.75 ± 19.02 ng/L, respectively, P = 0.292), IL-8 (369.23 ±
98.58 vs 229.77 ± 35.26 ng/L, respectively, P = 0.217), and
IL-6 (74.94 ± 20.25 vs 24.48 ± 10.31 ng/L, respectively, P =
0.050).
In summary, in this report we have demonstrated that intra-
cellular cholesterol ester content of monocyte-derived foam
cells after oxLDL incubation in vitro is variable among sub-
jects, and these diﬀerences are associated with the presence
of tendon xanthomas in subjects with FH. Besides, we have
highlighted a promising set of candidate genes involved in
macrophage foam cell development that could explain the for-
mation of tendon xanthomas in FH. The described macro-
phage gene expression diﬀerences could indicate that
macrophages from FH subjects TX+ compared to those
TX show a diﬀerential response to oxLDL since (1) they un-
dergo an upregulation of genes involved in remodelling their
environment, and (2) they show a more immunophenotype
M. Artieda et al. / FEBS Letters 579 (2005) 4503–4512 4511and a higher inﬂammatory response, altering their inﬂamma-
tory repertoire. Besides, the higher inﬂammatory response
was veriﬁed in plasma samples from FH subjects TX+ who
showed increased concentrations of tryptase, TNF-a, IL-8
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